Images List Premium Download Classic

Infectious

Infectious-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Biometric disease growth prediction
International Business Machines Corporation
June 14, 2018 - N°20180165419

Embodiments include methods, systems and computer program products for patterning and predicting the growth of infectious diseases through analysis of portable objects. Aspects include receiving biometric data from a plurality of nodes.
Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof
Tapimmune Inc.
June 14, 2018 - N°20180163226

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Methods of optimizing nucleotide sequences encoding engineered influenza proteins
Sanofi Pasteur, Inc.
June 14, 2018 - N°20180162914

The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers.
Infectious Patent Pack
Download 268+ patent application PDFs
Infectious Patent Applications
Download 268+ Infectious-related PDFs
For professional research & prior art discovery
inventor
  • 268+ full patent PDF documents of Infectious-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Infectious plasmodium sporozoites grown in vitro
Sanaria Inc.
June 14, 2018 - N°20180161413

The application is directed to in vitro-reared plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious plasmodium sporozoites (spz) of human host range, particularly p.
Extended protection protein vaccines against infectious agents
Cyvax, Inc.
June 14, 2018 - N°20180161412

Protein-based vaccines against infectious agents, including malaria and zika virus, are described. The protein-based vaccines include an antigen domain and an immature dendritic cell targeting domain and are administered in combination with an adjuvant..
Methods of obtaining mononuclear blood cells and uses thereof
Biolinerx Ltd.
June 14, 2018 - N°20180161366

Methods of obtaining mononuclear blood cells are provided. Also provided are methods of using the obtained cells for treating diseases such as cancer, infectious disease, autoimmune disease, allergy, and graft rejection..
Infectious Patent Pack
Download 268+ patent application PDFs
Infectious Patent Applications
Download 268+ Infectious-related PDFs
For professional research & prior art discovery
inventor
  • 268+ full patent PDF documents of Infectious-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for the treatment of infections and tumors
President And Fellows Of Harvard College
June 07, 2018 - N°20180155430

Pd-1 antagonists are disclosed that can be used to reduce the expression or activity of pd-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these pd-1 antagonists in conjunction with an antigen from the infectious agent or tumor.
Antibody molecules to pd-1 and uses thereof
President And Fellows Of Harvard College
June 07, 2018 - N°20180155427

Antibody molecules that specifically bind to pd-1 are disclosed. The anti-pd-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders..
Novel anti-infective compound
Eberhard Karls Universitaet Tuebingen
June 07, 2018 - N°20180155397

The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic ...
Compositions and methods for the treatment of inflammation and pain
Cellix Bio Private Limited
June 07, 2018 - N°20180155287

The invention relates to the compounds of formula i, formula ii, formula iii, formula iv and formula v or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, formula ii, formula iii, formula iv or formula v and methods for the treatment of inflammation and pain may ...
System and method for sterilizing and/or deimmunizing an object
Oneighty°c Technologies Corporation
June 07, 2018 - N°20180154030

A system for sterilizing and/or deimmunizing an object includes a stationary chamber at ambient pressure is configured to store an object to be sterilized and/or deimmunized therein. A solvent delivery subsystem is coupled to the chamber and configured to apply a directed volume of a non-toxic aqueous solvent to coat and wet the object to optimally hydrate proteins ...
Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
Biotropics Malaysia Berhad
June 07, 2018 - N°20180153950

A method for stimulating or enhancing the immune system with a composition that includes a eurycoma longifolia aqueous extract. Also provided is a method for reducing the risk of infectious disease by administering the composition.
Bacterial detection cartridge
Becton Dickinson And Company
May 31, 2018 - N°20180148760

Described herein are methods and apparatus for rapid detection of microorganisms in biological samples (e.g. Blood) for analysis to determine the presence or absence of infectious microorganisms in the samples.
Infectious Patent Pack
Download 268+ patent application PDFs
Infectious Patent Applications
Download 268+ Infectious-related PDFs
For professional research & prior art discovery
inventor
  • 268+ full patent PDF documents of Infectious-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Deuterated o-sulfated beta lactam hydroxamic acids and deuterated n-sulfated beta lactams
Skyline Antiinfectives, Inc.
May 31, 2018 - N°20180148439

Provided herein are deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.. .
Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
Iowa State University Research Foundation, Inc.
May 31, 2018 - N°20180147275

The present invention relates to infectious dna clones, infectious chimeric dna clones of porcine circovirus (pcv), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (pmws) caused by pcv2. The new chimeric infectious dna clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic pcv1 in which the immunogenic orf gene of the ...
Ipn virus genome mutations and codon interactions
Fvg Limited
May 31, 2018 - N°20180147274

The present invention relates generally to infectious pancreatic necrosis virus (ipnv) and specifically to further characterisation of the genetic stability of ipnv genome. More in particular, the invention relates to greater appreciation and understanding of the frequency of mutagenesis and codon interactions that influence the replication capabilities, virulence and immunogenicity of the virus.
Hepatocytes and hepatic non-parenchymal cells, and methods for preparation thereof
The University Of Tokyo
May 31, 2018 - N°20180147242

The present invention pertains to hepatocytes, liver progenitor cells, cholangiocytes, liver sinusoidal endothelial progenitor cells, liver sinusoidal endothelial cells, hepatic stellate progenitor cells, hepatic stellate cells, and liver cellular tissue models, as well as to methods for preparing these cells. The present invention also pertains to a cell fraction comprising liver progenitor cells, liver sinusoidal endothelial progenitor cells, or hepatic ...
Methods and compositions for the activation of gamma-delta t-cells
American Gene Technologies International Inc.
May 24, 2018 - N°20180142258

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta t-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.. .
Methods and compositions for the activation of gamma-delta t-cells
American Gene Technologies International Inc.
May 24, 2018 - N°20180142257

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta t-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.. .
Methods and compositions for the treatment of cancer or other diseases
City Of Hope
May 24, 2018 - N°20180142239

The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function.
Targeted nanocarriers for targeted drug delivery of gene therapeutics
Rodos Biotarget Gmbh
May 24, 2018 - N°20180140717

A targeted nanocarriers also termed nanomedicines and methods of preferentially, or actively, targeting and delivering a tool for gene transfer or genome editing (i.e., a plasmid or a restriction enzyme such as a zinc finger nuclease, a crispr/cas system, or a talen) or a tool for gene silencing or post-transcriptional regulation of gene expression (i.e., a microrna, ...
Loading